Imunon, Inc.

IMNN Healthcare Biotechnology

Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00. In the quarter to June 2026, EPS grew 71.1% and free cash flow fell 4.24%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.02 0.04 −3.77%
Market cap
$6.0M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
2/9
Altman Z
−12.47
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.82 1.59 2.32 1.73
Net Debt/EBITDA
0.52 1.16 2.15 1.59
Debt/Equity
1.32 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.59) (0.79) (1.72) (1.51)
Book value per Share
0.80 0.67 3.33 1.39
Free Cash Flow
(3.09) (3.99) (3.66) (4.44)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates